- Home
- NVNI vs NXTC Comparison
NVNI vs NXTC Comparison
Compare NVNI & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- NXTC
- Stock Information
- Founded
- NVNI 2019
- NXTC 2015
- Country
- NVNI Brazil
- NXTC United States
- Employees
- NVNI N/A
- NXTC N/A
- Industry
- NVNI
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- NVNI
- NXTC Health Care
- Exchange
- NVNI Nasdaq
- NXTC Nasdaq
- Market Cap
- NVNI 10.4M
- NXTC 9.3M
- IPO Year
- NVNI N/A
- NXTC 2019
- Fundamental
- Price
- NVNI $0.16
- NXTC $0.46
- Analyst Decision
- NVNI
- NXTC Strong Buy
- Analyst Count
- NVNI 0
- NXTC 2
- Target Price
- NVNI N/A
- NXTC $3.50
- AVG Volume (30 Days)
- NVNI 3.6M
- NXTC 270.4K
- Earning Date
- NVNI 05-07-2025
- NXTC 05-05-2025
- Dividend Yield
- NVNI N/A
- NXTC N/A
- EPS Growth
- NVNI N/A
- NXTC N/A
- EPS
- NVNI N/A
- NXTC N/A
- Revenue
- NVNI $23,558,620.00
- NXTC N/A
- Revenue This Year
- NVNI $25.91
- NXTC N/A
- Revenue Next Year
- NVNI $21.68
- NXTC N/A
- P/E Ratio
- NVNI N/A
- NXTC N/A
- Revenue Growth
- NVNI 38.59
- NXTC N/A
- 52 Week Low
- NVNI $0.16
- NXTC $0.22
- 52 Week High
- NVNI $12.19
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- NVNI 30.09
- NXTC 52.76
- Support Level
- NVNI $0.16
- NXTC $0.38
- Resistance Level
- NVNI $0.17
- NXTC $0.44
- Average True Range (ATR)
- NVNI 0.02
- NXTC 0.07
- MACD
- NVNI 0.06
- NXTC 0.03
- Stochastic Oscillator
- NVNI 30.49
- NXTC 85.82
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.